To help achieve this goal, this review focuses on the factors that recruit Tregs to the tumor site, promote their differentiation and activity in the TME as well as biomarkers that distinguish tumor-specific Tregs from tumor-specific CD4+ effector T cells and self-specific Tregs that protect against autoimmunity. Here, CD4 is linked to neoplasm.